Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis.

Pharmacogenomics - 1 Jan 2025

Tavkar Vrunda, Goyal Ankita, Chopra Vishal, Garg Kranti, Sharma Siddharth

Abstract excerpt

BACKGROUND: Anti-tuberculosis drug-induced liver injury (AT-DILI) is one of the significant adverse effects of first-line tuberculosis therapy, frequently resulting in treatment discontinuation. Genetic polymorphisms in N-acetyltransferase 2 (NAT2), a key enzyme in the metabolism of isoniazid (an anti-TB drug), are suggested to influence AT-DILI susceptibility. METHODS: A meta-analysis of published studies was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemical and Drug Induced Liver Injury

Share to NAT2 gene

Share to Genetic Predisposition to Disease

Share to Isoniazid

Share to Polymorphism, Single Nucleotide

Share to Tuberculosis

Source

Open in PubMed Open full text

Identifiers

PMID: 41657030
DOI: 10.1080/14622416.2026.2624364
PMCID: PMC12915812

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis.PMID 41657030Read ↗

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.Semantic proximity Read ↗

NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.Semantic proximity Read ↗

Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis.Semantic proximity Read ↗

NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.Semantic proximity Read ↗

NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.Semantic proximity Read ↗

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.Semantic proximity Read ↗

Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidenceSemantic proximity Read ↗

NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.Semantic proximity Read ↗

NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic CohortSemantic proximity Read ↗

Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.